Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 1 |
2008 | 1 |
2009 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.
Cancer Biol Ther. 2006 Oct;5(10):1361-8. doi: 10.4161/cbt.5.10.3226. Epub 2006 Oct 26.
Cancer Biol Ther. 2006.
PMID: 16969069
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.
Zhang Y, Su H, Rahimi M, Tochihara R, Tang C.
Zhang Y, et al.
Int J Cancer. 2009 Nov 1;125(9):2021-8. doi: 10.1002/ijc.24540.
Int J Cancer. 2009.
PMID: 19588487
Free PMC article.
Item in Clipboard
Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways.
Yu H, Gong X, Luo X, Han W, Hong G, Singh B, Tang CK.
Yu H, et al.
Cancer Biol Ther. 2008 Nov;7(11):1818-28. doi: 10.4161/cbt.7.11.6847. Epub 2008 Nov 24.
Cancer Biol Ther. 2008.
PMID: 18787418
Item in Clipboard
Cite
Cite